Office of Commercialization and Economic Development
Office of Technology Commercialization

Modification of Capsule Endsocopy for Enhanced Ability to Detect Gastrointestinal Lesions

Technology #05-0072

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Pauline Lund
Managed By
Matthew Howe
Commercialization Manager 919.966.3929
Patent Protection
US Patent US 8900133

An enhanced capsule endoscopy technology has been developed. In vivo experiments in mice using a near-infrared fluorescent probe activated in vivo by cathepsin B demonstrated that biochromoendoscopy (BCE) was able to precisely image adenomatous polyps and distinguish them from benign polyps and inflammatory lesions. BCE uses specific wavelength filters in combination with select activated probes to differentiate between benign, pre-malignant and malignant lesions in the gastrointestinal tract.

Advantages:

•  Detects benign or inflammatory gastrointestinal lesions

•  Specifically identifies lesions in a background of chronic inflammation

•  Can detect previously hard-to-identify flat lesions